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Michael Wayne*, Justin Steele, Mazen Iskandar and Avram CoopermanAbstract: Robotic pancreatic surgery offers technical advantages, and has been applied across many surgical
specialties. We report an initial experience of 12 distal pancreatic resections for benign tumors from an established
pancreatic center with previous general and biliary laparoscopic experience. Of a total of 12 patients, 7 were
women; the mean age was 55.5 years, and the lesions included 8 distal intraductal papillary mucinous tumors, 1
insulinoma and in 3 a non-functioning neuroendocrine tumor. All operations were performed in between 90 and
180 minutes, and blood loss and hospital stay were minimal.Review
Introduction
The application and popularity of robotic surgery
increase annually [1]. Robotics offer several advantages
including three-dimensional visualization, enhanced
dexterity through articulated instruments, higher mag-
nification of the surgery site, and ‘arms’ that provide
fixed traction and exposure [1-3]. Its adaptation in pan-
creatic surgery has lagged for technical, philosophical
and economic reasons. We are an established hepatobiliary
and pancreatic center, experienced in open pancreatic,
and open and laparoscopic biliary surgery, but not robotic
or laparoscopic pancreatic surgery. We report our first 12
robotic pancreatic resections, and review the relevant
literature.
Methods
Between 14 November 2011 and 9 August 2012, 12
patients underwent pancreatic robotic surgery, using the
DaVinci Surgical System (Intuitive Surgical Inc, 1266 Kifer
Rd, Sunnyvale Calif 94066). The patients were seven
women and five men. Ages ranged from 33 to 78 years,
with a mean of 55.5 years and a median of 57 years. The
indications for surgery were a distal intraductal papillary
mucinous neoplasm (IPMN) in eight patients, an
insulinoma in one patient and non-functioning neuroendo-
crine tumor (NET) in three patients (Table 1). The* Correspondence: waynedocny@yahoo.com
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reproduction in any medium, provided the oroperations included one central pancreatectomy (CP), ten
distal pancreatectomies without splenectomy (DP), and
one distal pancreatectomy with splenectomy (DP + S).
Results
Operative times ranged from 1 hour and 30 minutes to
3 hours with a median of 2 hours and 50 minutes and a
mean of 2 hours and 22 minutes. Blood loss was 100 cm3
or less in ten patients, 150 ml in one patient and 350 ml
in another. The length of stay was 3 days in two patients,
4 days in nine patients, and 5 days in one patient. There
were no fistulas or significant complications (Table 2).
Discussion
In 2003, Giulianotti et al. reported a series of robotic
abdominal operations including the first pancreatic
resection [4], and Melvin et al. reported a robotic excision
of a neuroendocrine tumor [5]. While robotic operations
have tripled between 2007 and 2010, there have been few
reports of robotic pancreatic surgery [1,6]. Until recently
most pancreatic surgery was performed for pancreatic
adenocarcinoma, and most often required a Whipple
operation, which can be intricate, lengthy and with
significant morbidity [7,8]. Most distal pancreatic adeno-
carcinomas are large, rarely resectable or curable [7]. Why
add robotics, time, cost and difficulty to an already grim
situation?
The worldwide increase in body imaging has detected
smaller, asymptomatic, and incidental pancreatic lesions
[9,10]. These include cystic and neuroendocrine tumors,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics in present series (n = 12)
Category No.
Gender, female:male 7:5
Age in years, mean (range) 55.5 (33 to 78)
Indications:





Distal pancreatectomy with splenectomy 1
Central pancreatectomy 1













Waters et al. [2] 17 4 h and 58 m 4 279 0
Kang et al. [3] 20 4 h and 58 m 7.18 372 -
Daoudi
et al. [11]
30 4 h and 53 m 6.1 212 14
Giulianotti
et al. [12]
46 5 h and 31 m 9.3 323 9
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[9,10]. When surgery is indicated, the small size and
absent vascular involvement favor laparoscopy or robotics.
Most robotic pancreatic procedures (60% to 70%) are
performed for benign lesions less than 3 cm, reflecting
selection bias and sound judgment [2,3,11,12].
We were late to adopt robotic pancreatic surgery
since open distal resections took less than 1 h and
pancreaticoduodenal resections 2.5 h, both performed with
minimal blood loss (<150 cm3), short hospital stay (5 to
8 days) and few pancreatic fistulas (0% to 6%) [13,14]. We
reconsidered, as patients inquired and requested robotics.
Our first robotic resection took 3 hours, and the most re-
cent 1 hour and 30 minutes. The mean time was 2 hours
and 22 minutes. There are four published case series of
robotic distal pancreatectomy. The number of patients
and operative times for each were: 17 patients (4 hours
and 58 minutes) [2], 20 patients (5 hours and 40 minutes)Table 2 Results for present series
Category Finding
Gender, female:male 7:5
Operative time in hours (h) and
minutes (m), mean (range)
2 h and 22 m
(1 h and 30 m to 3 h)
Estimated blood loss:
<100 ml 10
100 to 200 ml 1








Others 0[3], 30 patients (4 hours and 5 minutes) [11] and 46 pa-
tients (5 hours and 31 minutes) [12] (Table 3).
Our series included one central resection. Three reports
of robotic central resection include three, five, and nine
patients with mean operating times from 5 hours and 20
minutes to 8 hours 0” [1,14,15]. The fistula rates were
one in three [15], one in five [16] and seven in nine [1] and
the hospital stay ranged from 9 to 28 days. The operating
time was influenced by the distal pancreatic anastomosis,
that is, pancreaticogastrostomy, or pancreaticojejunostomy.
We favor closure rather than anastomoses of the distal
duct in central resections, as it shortens hospital stay, and
operating time, minimizes fistula rates and does not
increase exocrine insufficiency [17].
The robotic pancreatic studies indicate satisfaction with
robotics, fewer conversions to open surgery and greater
splenic preservation as compared to laparoscopy [1,3].
A large laparoscopic pancreatic experience generally
precedes pancreatic robotic surgery. Despite this experi-
ence, most reported robotic operations took at least 5 h,
double our initial experience. Our lack of laparoscopic
pancreatic experience was balanced by the benefits of a
large open experience, which provided intimate familiarity
with pancreatic anatomy, and insights into case selection,
and intraoperative decision making.
The cost of robotic surgery is a valid concern. Waters
et al. compared the cost of robotic distal pancreatectomy
(R) to open (O) and laparoscopic distal pancreatectomy (L)
in 77 cases [2]. The mean operating times and hospital stay
were for O (3 hours and 42 minutes; 8 days), for L (4 hours
and 5 minutes; 6 days), and for R (4 hours and 58 minutes;
4 days). The total cost for R, O and L were US$10,588, US
$12,986, and US$16,059. The higher operative cost for ro-
botics was offset by a shorter stay for robotic procedures.
Our operating room charges were slightly higher for
robotics (R) compared to open surgery (O) US$2,180.48
versus US$1,750.09 but were offset by a shorter hospital
stay, 3.9 days (R) versus 6.5 (O). Kang et al. noted in
Korea that costs were 2.5 times higher for robotic versus
laparoscopic distal pancreatic resections, not offset by
hospital costs. [3].
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advantages benefit patients and facilitate surgery in appro-
priately selected cases.
Conclusions
In all, 12 patients with benign pancreatic tumors underwent
robotic pancreatic distal resection (11), and central resec-
tion (1). Operative times ranged from 1 hour and 30 mi-
nutes to 3 hours, blood loss less than 100 cm3 in ten
patients, 150 cm3 in one patient and 350 cm3 in another.
Hospital stay was 3 to 4 days for 11 patients and 5 days for
1 patient. Careful selection of patients and a large pancre-
atic experience allow satisfactory outcomes after pancreatic
resections and may equalize or outweigh minimally invasive
experience.
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